Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M

This article was originally published in The Pink Sheet Daily

Executive Summary

The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.

You may also be interested in...



Pfizer's Staph Vaccine: Can Narrow Trial Population Support Broader Claim?

US FDA advisory committee will weigh in on clinical development plan for SA4Ag, an S. aureus vaccine for prophylactic use, including whether safety and efficacy data from an ongoing, Phase II trial in spinal surgery patients are generalizable to other elective orthopedic surgical populations.

GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX

Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.

GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX

Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.

Related Content

Topics

UsernamePublicRestriction

Register

PS069943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel